+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID00315380

Longitudinal Study to Identify Biomarkers for Monitoring Eosinophilic Granulomatosis With Polyangiitis

Led by University of Pennsylvania · Updated on 2026-08-28

700

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Eosinophilic granulomatosis with polyangiitis EGPA is a rare immune system disorder characterized by asthma, high levels of eosinophils in the blood, and inflammation of blood vessels affecting various organs. This study aims to identify new biological markers, called biomarkers, that can help assess the severity and activity of EGPA over time. These biomarkers could improve monitoring and guide future treatments for people with EGPA. Participants in this observational study will attend visits every six months or annually, during which blood and urine samples will be collected. At each visit, a physical exam will be performed, medical and medication histories reviewed, and participants will complete questionnaires about their disease activity, health status, and lifestyle factors such as tobacco, alcohol, and drug use. Throughout the study, researchers will measure the biomarkers to evaluate disease activity and how patients respond to treatment. The main goal is to discover biomarkers that can predict clinical outcomes for EGPA. The study will continue until 2028, with ongoing monitoring and assessments at regular intervals to gather comprehensive data on the disease.

CONDITIONS

Brief Title

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here